Cidara Therapeutics (CDTX) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Climate Environment Environmental Escape Materials Nature Offset Package Packaging Pandemic Toxic Waste Access African American Asian Benefits Black California Consumer Privacy Act Charitable Collective Bargaining Community Culture Customer Cyber Cyber Security Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Resources Incident Injuries Injury Labor Standards Latinx LGBTQ Minority Perquisites Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Anti-corruption Antitrust Assessment Assurance Audit Bonus Bribery Chronic Classified Commitment Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Oversee Oversight Perquisite Pledging Procurement Proxy Access Proxy Contest Purpose Quality Standard R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Targets Tax Tax Gross Up Transparency Transparent Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 23, 2021, Cidara Therapeutics, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 26, 2021, the record date for the Annual Meeting, 48,289,795 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting, as well as the final voting results with respect to each matter, is set forth below.
Proposal 1. Election of Directors
The Company’s stockholders elected the three persons listed below as Class III Directors, each to serve until the Company’s 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:

	Votes For	Votes Withheld	Broker Non-Votes

Carin Canale-Theakston	25,593,326	106,361	9,766,423
Timothy R. Franson, M.D.	23,407,536	2,292,152	9,766,423
Chrysa Mineo	23,728,379	1,971,308	9,766,423

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company’s Board of Directors to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The final voting results are as follows:

Votes For						Votes Against						Abstentions						Broker Non-Votes

35,317,123						30,284						118,704						—

Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows:

Votes For						Votes Against						Abstentions						Broker Non-Votes

24,880,078						454,234						365,375						9,766,423

Proposal 4. Indication, on an Advisory Basis, of the Preferred Frequency of Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers
The Company’s stockholders indicated, on an advisory basis, the preferred frequency of one year for future stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows:

Votes for every 1 Year						Votes for every 2 Years						Votes for every 3 Years						Abstentions						Broker Non-Votes

25,341,456						26,622						240,553						91,057						9,766,423